Business Context and Reporting Period
Company: Icecure Medical Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: November 2025 (Specific date: November 3, 2025)
Context: The filing serves to distribute a press release regarding clinical outcomes for the Company's cryoablation system when combined with radiation therapy for Non-Small Cell Lung Cancer (NSCLC).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report of a material event (clinical data release) and does not contain financial statements or operational financial metrics.
Material Changes
No financial material changes versus prior periods are reported in this filing. The material event disclosed is the publication of clinical data indicating a 92% disease-specific 5-year survival rate for NSCLC patients treated with the Company's cryoablation system combined with radiation therapy.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release highlighting successful treatment outcomes for NSCLC.
Guidance/Outlook: The filing text does not provide specific financial guidance or future operational outlook beyond the clinical success noted.
Risks/Contingencies: No specific risks or contingencies are detailed in the text of this Form 6-K summary.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed clinical study parameters and limitations.
- Confirm the regulatory status of the cryoablation system in key markets following this clinical data release.
- Review subsequent filings for any impact of this clinical data on the Company's commercial strategy or partnership discussions.
- Check the Company's latest Form 20-F for the most recent audited financial position, as this 6-K contains no financial data.